Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

CCAAT/enhancer binding protein β and its role in autoimmune diseases: a promising therapeutic target

Wang YY., Xu Y., Chen YL., Wei W., Chang Y.

Narrative Review on Neuroinflammation, Chronic Inflammation, Autoimmune Research, published in J Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Transl Med (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41888827
PMCID
PMC13141571
DOI
10.1186/s12967-026-08037-w

Abstract (original English)

BACKGROUND: The CCAAT/enhancer binding protein β (C/EBPβ) is a key transcription factor regulating immune homeostasis. Although its oncogenic roles are well-established, its context-dependent functions in autoimmune diseases, which affect 5–10% of the global population, remain incompletely understood. This review aims to synthesize current knowledge on C/EBPβ’s paradoxical roles in autoimmunity and evaluate its emerging therapeutic potential. MAIN BODY: We detail how C/EBPβ, through its antagonistic isoforms LAP*/LAP (activator) and LIP (repressor), operates as both a pathogenic driver and a protective regulator in a cell-type-specific manner across major autoimmune conditions. In rheumatoid arthritis, it coordinates synovitis, cartilage degradation, and bone erosion. In lupus nephritis, it promotes podocyte pyroptosis. In multiple sclerosis, it drives pathogenic Th17 differentiation and microglial activation. Conversely, in ulcerative colitis, it can also facilitate anti-inflammatory M2 macrophage polarization. Critically, we evaluate emerging strategies to target this transcription factor, including isoform-selective inhibitors and peptide-based degraders, which challenge its historical classification as “undruggable” and open novel therapeutic avenues. CONCLUSIONS: C/EBPβ emerges as a pivotal, context-dependent orchestrator of autoimmune pathogenesis. Understanding its isofo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansAutoimmune DiseasesCCAAT-Enhancer-Binding Protein-betaProtein IsoformsMolecular Targeted Therapy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research